Petra Bártová, Eva Augste, Filip Strouhal, Jan Krhut, Martin Slovák, Lukáš Peter, Martin Schmidt, David Školoudík
{"title":"经皮腓电神经调节（Peroneal eTNM）治疗原发性震颤","authors":"Petra Bártová, Eva Augste, Filip Strouhal, Jan Krhut, Martin Slovák, Lukáš Peter, Martin Schmidt, David Školoudík","doi":"10.1155/ane/5231029","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Given the limitations of the currently available treatment options for essential tremor (ET), the development of a safe and effective method to manage ET is warranted. The aim of this study is to investigate the safety and feasibility of peroneal electrical transcutaneous neuromodulation (peroneal eTNM) in patients with ET.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Patients enrolled in the study were treated with peroneal eTNM daily for 30 min over 6 weeks, followed by a 6-week follow-up period without stimulation. Peroneal eTNM was administered alongside their chronic medication.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 12 patients (eight men, mean age 60.2 ± 17.7 years, mean disease duration 9.2 ± 7.8 years) were enrolled. All patients were able to use the stimulation at home without assistance. During the study, only two transient treatment-related adverse events were reported. Seven patients (58.3%) reported subjective improvement using the Patient Global Impression of Improvement questionnaire at the end of treatment (EoT), and five patients (41.7%) reported improvement at the end of study (EoS). We observed a significant reduction in the total Essential Tremor Rating Assessment Scale (TETRAS) score, with median (IQR) values decreasing from 38.3 (30.5–49.0) at baseline to 36.5 (20.8–41.5) at EoT and 34.5 (13.0–36.8) at EoS. Similarly, tremor severity, as measured visually and with an accelerometer, showed significant improvement. However, no significant changes were observed in tools assessing quality of life and general disability.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This pilot study demonstrates that peroneal eTNM is safe and feasible for patients with ET. Despite the limited sample size, ET patients treated with peroneal eTNM showed significant improvement in tremor severity as measured by both subjective and objective tools. Future studies with a larger sample size and sham-controlled design are needed to confirm these findings and further validate the potential of peroneal eTNM in the treatment of patients with ET.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>ClinicalTrials.gov identifier: NTC06036368</p>\n </section>\n </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2025 1","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5231029","citationCount":"0","resultStr":"{\"title\":\"Peroneal Electrical Transcutaneous Neuromodulation (Peroneal eTNM) in the Treatment of Essential Tremor\",\"authors\":\"Petra Bártová, Eva Augste, Filip Strouhal, Jan Krhut, Martin Slovák, Lukáš Peter, Martin Schmidt, David Školoudík\",\"doi\":\"10.1155/ane/5231029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>Given the limitations of the currently available treatment options for essential tremor (ET), the development of a safe and effective method to manage ET is warranted. The aim of this study is to investigate the safety and feasibility of peroneal electrical transcutaneous neuromodulation (peroneal eTNM) in patients with ET.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Patients enrolled in the study were treated with peroneal eTNM daily for 30 min over 6 weeks, followed by a 6-week follow-up period without stimulation. Peroneal eTNM was administered alongside their chronic medication.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 12 patients (eight men, mean age 60.2 ± 17.7 years, mean disease duration 9.2 ± 7.8 years) were enrolled. All patients were able to use the stimulation at home without assistance. During the study, only two transient treatment-related adverse events were reported. Seven patients (58.3%) reported subjective improvement using the Patient Global Impression of Improvement questionnaire at the end of treatment (EoT), and five patients (41.7%) reported improvement at the end of study (EoS). We observed a significant reduction in the total Essential Tremor Rating Assessment Scale (TETRAS) score, with median (IQR) values decreasing from 38.3 (30.5–49.0) at baseline to 36.5 (20.8–41.5) at EoT and 34.5 (13.0–36.8) at EoS. Similarly, tremor severity, as measured visually and with an accelerometer, showed significant improvement. However, no significant changes were observed in tools assessing quality of life and general disability.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>This pilot study demonstrates that peroneal eTNM is safe and feasible for patients with ET. Despite the limited sample size, ET patients treated with peroneal eTNM showed significant improvement in tremor severity as measured by both subjective and objective tools. Future studies with a larger sample size and sham-controlled design are needed to confirm these findings and further validate the potential of peroneal eTNM in the treatment of patients with ET.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>ClinicalTrials.gov identifier: NTC06036368</p>\\n </section>\\n </div>\",\"PeriodicalId\":6939,\"journal\":{\"name\":\"Acta Neurologica Scandinavica\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-10-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5231029\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Neurologica Scandinavica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/ane/5231029\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Neurologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/ane/5231029","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Peroneal Electrical Transcutaneous Neuromodulation (Peroneal eTNM) in the Treatment of Essential Tremor
Objectives
Given the limitations of the currently available treatment options for essential tremor (ET), the development of a safe and effective method to manage ET is warranted. The aim of this study is to investigate the safety and feasibility of peroneal electrical transcutaneous neuromodulation (peroneal eTNM) in patients with ET.
Methods
Patients enrolled in the study were treated with peroneal eTNM daily for 30 min over 6 weeks, followed by a 6-week follow-up period without stimulation. Peroneal eTNM was administered alongside their chronic medication.
Results
A total of 12 patients (eight men, mean age 60.2 ± 17.7 years, mean disease duration 9.2 ± 7.8 years) were enrolled. All patients were able to use the stimulation at home without assistance. During the study, only two transient treatment-related adverse events were reported. Seven patients (58.3%) reported subjective improvement using the Patient Global Impression of Improvement questionnaire at the end of treatment (EoT), and five patients (41.7%) reported improvement at the end of study (EoS). We observed a significant reduction in the total Essential Tremor Rating Assessment Scale (TETRAS) score, with median (IQR) values decreasing from 38.3 (30.5–49.0) at baseline to 36.5 (20.8–41.5) at EoT and 34.5 (13.0–36.8) at EoS. Similarly, tremor severity, as measured visually and with an accelerometer, showed significant improvement. However, no significant changes were observed in tools assessing quality of life and general disability.
Conclusion
This pilot study demonstrates that peroneal eTNM is safe and feasible for patients with ET. Despite the limited sample size, ET patients treated with peroneal eTNM showed significant improvement in tremor severity as measured by both subjective and objective tools. Future studies with a larger sample size and sham-controlled design are needed to confirm these findings and further validate the potential of peroneal eTNM in the treatment of patients with ET.
期刊介绍：
Acta Neurologica Scandinavica aims to publish manuscripts of a high scientific quality representing original clinical, diagnostic or experimental work in neuroscience. The journal''s scope is to act as an international forum for the dissemination of information advancing the science or practice of this subject area. Papers in English will be welcomed, especially those which bring new knowledge and observations from the application of therapies or techniques in the combating of a broad spectrum of neurological disease and neurodegenerative disorders. Relevant articles on the basic neurosciences will be published where they extend present understanding of such disorders. Priority will be given to review of topical subjects. Papers requiring rapid publication because of their significance and timeliness will be included as ''Clinical commentaries'' not exceeding two printed pages, as will ''Clinical commentaries'' of sufficient general interest. Debate within the speciality is encouraged in the form of ''Letters to the editor''. All submitted manuscripts falling within the overall scope of the journal will be assessed by suitably qualified referees.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
